Published in final edited form as:

Pancreatology. 2015 July ; 15(0): S61–S65. doi:10.1016/j.pan.2015.03.003.

Metabolic Reprogramming and Cell Fate Regulation in Alcoholic Liver Disease

Hidekazu Tsukamoto

Southern California Research Center ALPD and Cirrhosis and Department of Pathology, Keck School of Medicine of the University of Southern California, Greater Los Angeles VA Healthcare System, Los Angeles, California, USA

Abstract

Alcoholic liver disease (ALD) should be defined as a life-style metabolic disease. Its pathogenesis is driven by altered cell fate of both parenchymal and non-parenchymal liver cell types, contributing to different pathologic spectra. A critical turning point in progression of ALD is chronic alcoholic steatohepatitis (ASH) or alcoholic neutrophilic hepatitis (AH), which markedly predisposes patients to most devastating ALD sequela, cirrhosis and liver cancer. Our research identifies the pivotal roles of unique metabolic reprogramming in M1 activation of hepatic macrophages (HM) and myofibroblastic activation (MF) of hepatic stellate cells (HSC) in the genesis of inflammation and fibrosis, the two key histological features of chronic ASH and neutrophilic AH. For M1 HM activation, heightened proinflammatory iron redox signaling in endosomes or caveosomes results from altered iron metabolism and storage, promoting IKK/NF- κ B activation via interactive activation of p21ras, TAK1, and PI3K. For MF cell fate regulation of HSC, activation of the morphogen Wnt pathway caused by the nuclear protein NECDIN or the single-pass trans-membrane protein DLK1, reprograms lipid metabolism via MeCP2-mediated epigenetic repression of the key HSC quiescence gene *Ppar- γ* . Conclusions from these studies re-enforce the importance of metabolic reprogramming in cell fate regulation required for the pathogenesis of ALD.

Keywords

M1 macrophage activation; iron; hepatic stellate cells; morphogens

I. Metabolic Reprogramming of Hepatic Macrophages

Macrophage vs. neutrophilic inflammation in ALD

Inflammation is a key pathologic turning point for progression of alcoholic liver disease (ALD) and is manifested as chronic alcoholic steatohepatitis (ASH) characterized primarily

Address correspondence to: Hide Tsukamoto, Ph.D., D.V.M., Professor of Pathology, Director, Southern California Res. Center for ALPD and Cirrhosis, Keck School of Medicine of the University of Southern California, 1333 San Pablo Street, MMR-402, Los Angeles, CA 90089-9141, Courier: Los Angeles, CA 90033-9141, TEL: 323-442-5107, FAX: 323-442-3126, htsukamo@usc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

by mononuclear cell infiltration, perisinusoidal and pericellular fibrosis, and foamy hepatocellular degeneration. Some of these ASH patients develop neutrophilic alcoholic hepatitis (AH) with hepatic and systemic complications leading to the mortality as high as 50–60%. Hepatic macrophages are considered as a central effector for ASH, which undergoes M1 proinflammatory activation via pathways involving endotoxin-TLR4 [1]. In AH, inflammation shifts to neutrophilic infiltration, the histologic hallmark of AH, for reasons that are yet to be defined. This shift is also reproduced in a mouse model which recapitulates the risk factors known for AH patients in the US including binge drinking [2]. It is generally believed that M1 macrophage activation serves as a predisposing condition required for progressive ASH or neutrophilic infiltration in AH triggered by an additional hit. For this reason, the mechanisms underlying M1 macrophage activation remains a focus of active investigation.

Link between macrophage iron and chronic inflammatory diseases

Chronic liver diseases such as ALD [3], non-alcoholic fatty liver disease (NAFLD), and viral hepatitis [4, 5], are accompanied by increased hepatic iron content that in turn exacerbates the disease process. In an animal model, chronic alcohol intake increases iron content in both hepatocytes and hepatic macrophages [6]. In a non-alcoholic steatohepatitis (NASH) animal model, erythrophagocytosis and resultant iron loading promote oxidant stress, inflammation, and liver fibrosis [7]. In fact, iron accumulation is not restricted to liver diseases but is also evident in other chronic inflammatory diseases including atherosclerosis [8], pulmonary fibrosis [9] and neurodegenerative diseases such as Parkinson's disease [10] and Alzheimer's disease [11], suggesting iron accumulation is a common consequence or even cause of chronic inflammation and tissue damage. The causal relationship is suggested for liver diseases as an iron reduction therapy by phlebotomy improves the plasma aminotransferase level, the indicator for liver damage, in patients with NAFLD [12] and viral hepatitis [13]. The most prevalent hypothesis for the causal mechanism of iron is the Fenton pathway generating a hydroxyl radical and causing oxidative tissue injury. Thus, it is not surprising that any additional incremental increase in tissue iron content sensitizes the organs for oxidative damage caused by primary etiological factors. This is exemplified by ALD that is clearly exacerbated by dietary iron supplementation in animal model [14] or increased hepatic iron content due to hemochromatosis in man [15].

We proposed 17 years ago, a notion that there must be a more direct mechanism than the Fenton reaction, by which iron promotes inflammation in chronic liver disease via its role in hepatic macrophages (HM). Treatment of rats subjected to bile duct ligation and transection (BDL) with 1,2 dimethyl-3-hydroxypyrid-4-one (L1), a lipophilic iron chelator, markedly attenuated NF- κ B activation and TNF- α and IL-6 expression in HM isolated from the model, as well as cholestatic liver damage [16]. HM isolated from a rat model of ALD had a ~80% increase in non-heme iron content and substantially activated NF- κ B as compared to HM from pair-fed control rats. *Ex vivo* treatment of HM from the ALD model with L1 eliminated both the increment in non-heme iron content and NF- κ B activation [17], suggesting the critical role of an expansion of the chelatable pool of iron in HM in NF- κ B activation. We also observed a slight decrease (~15%) in the non-heme iron content of HM from the control rats by L1 treatment, suggesting that there exists a fraction of the chelatable

iron pool even in normal HM. In fact, we showed this chelatable pool plays a pivotal role in NF- κ B activation in HM from normal rats.

Identification of macrophage iron signaling ([LMW-Fe]i) for NF- κ B activation

The molecular basis for the role of chelatable iron pool in HM NF- κ B activation was subsequently revealed by identification of a transient rise in intracellular low molecular weight iron complexes ([LMW-Fe]i) at 1–2 min after LPS stimulation prior to IKK activation at 15–30 min and increased p65/p50 binding to the κ B element at 30–60 min [18]. The treatment of HM with the iron chelator abolished LPS-stimulated [LMW-Fe]i, IKK activation and NF- κ B binding. Loss-of-function approaches disclosed that peroxynitrite (ONNO-) was responsible for LPS-induced [LMW-Fe]i [18], which in turn activated IKK via protein-protein interaction and activation of p21Ras, PI3K, and TAK1 in caveolin1-positive endocytic compartments [19]. For p21Ras and TAK1 activation mediated by [LMW-Fe]i, we showed c-Src activation by PTP2 inactivation and K63-linked polyubiquitination of TRAF6 were critical upstream events, respectively (see a schematic summary shown in Fig. 1A and 1B). We then tested whether [LMW-Fe]i signaling is relevant to man. For this, we used peripheral blood monocytes isolated from normal human subjects. After purification of monocytes, we treated the cells with PMA overnight to promote macrophage differentiation as assessed by the expression of macrophage marker such as CD14 and CD68. After washing and resting the cells, these macrophages were tested for [LMW-Fe]i stimulated with peroxynitrite, the immediate upstream effector for the signaling. Indeed, macrophages derived from PMA-treated human monocytes, exhibited the [LMW-Fe]i response while monocytes without PMA treatment failed to show this response. More importantly, macrophages with acquired [LMW-Fe]i signaling, released 4~5 fold more TNF- α as compared to monocytes in response to peroxynitrite. Further, the iron chelator treatment (L1) abrogated both [LMW-Fe]i and TNF- α release by macrophages. These results demonstrate that: 1) [LMW-Fe]i signaling is relevant to man and a function acquired by differentiated macrophages; and 2) acquisition of this iron signaling confers the cells the ability to exhibit a maximal cytokine response [20].

Accentuated [LMW-Fe]i in ASH

How does [LMW-Fe]i signaling explain accentuated IKK and NF- κ B activation in iron-loaded HM as seen in chronic liver disease? Is [LMW-Fe]i accentuated as a chelatable pool of iron expands in HM? These natural questions were subsequently addressed. Indeed, in HM isolated from the ASH model, an increased chelatable iron pool was directly responsible for enhanced [LMW-Fe]i signaling and NF- κ B activation [20]. To further confirm this causal relationship, we artificially increased the non-heme iron content in HM by a single subcutaneous injection of iron dextran which was gradually and relatively selectively taken up by macrophages. HM isolated from mice 2 weeks after a single subcutaneous injection of iron dextran (25mg/kg or 75mg/kg), had a 1.7 or 3.8 fold increase in non-heme iron content. This manipulation enhanced LPS or peroxynitrite induced [LMW-Fe]i and TNF- α release by HM *ex vivo*. Further, this treatment given prior to intragastric infusion of ethanol and a high fat diet, markedly aggravated ASH and even induces liver fibrosis within 4 weeks of feeding, supporting the pathologic significance of enhanced [LMW-Fe]i signaling for NF- κ B dependent proinflammatory cytokine expression in ALD

[20]. One can also enhance [LMW-Fe]i signaling by a genetic manipulation. RAW264.7 cells expressing high level of Nramp1, a late endosome iron transporter, has less non-heme iron content and a reduced chelatable pool of iron as compared to the cells with Nramp1 deficiency and an increased chelatable iron pool [21]. As predicted, the latter cells have a heightened [LMW-Fe]i response, accentuated IKK and NF- κ B activation, and more pronounced TNF- α release in response to LPS [18].

One may naturally wonder why iron accumulates in HM in chronic liver disease. Our screening for iron transporters and regulatory molecules in HM from the rat ALD model [20] showed ferroportin-1 (FPN1), a major iron exporter protein was induced in these cells, suggesting this change could not account for the increased non-heme iron content. Instead, FPN1 induction was likely an adaptive response to increased iron content as this major iron exporter is positively regulated by iron loading and erythrophagocytosis in J774 macrophages [22]. Indeed, iron treatment of cultured HM resulted in marked induction of FPN1 mRNA while L1 treatment causes its suppression [20]. We next determined the plasma levels of hepcidin, the most important iron-regulatory hormone primarily expressed by hepatocytes which causes degradation of FPN1 for its suppressive effect on iron efflux from intestinal cell basal membrane. However, the plasma pro-hepcidin levels were not different between alcohol and control diet fed animals. We then examined mRNA expression of transferrin receptor-1 (TfR1), and TfR2, as well as the hemochromatosis gene (Hfe) known to regulate transferrin-mediated iron uptake. This analysis demonstrated a 6-fold induction of TfR1 (a major receptor type in HM) but not of TfR2 and 2-fold induction in Hfe in HM from alcohol-fed animals [20]. TfR1 protein expression was also increased in these cells, suggesting enhanced iron uptake as a possible cause of iron accumulation. This notion was tested next by examining Fe59 uptake by HM from alcohol-fed and control animals in serum-containing medium. Indeed, HM from alcohol-fed animals exhibited an enhanced iron uptake rate as compared to the control cells. HFE is believed to upregulate TfR-mediated uptake of iron as demonstrated by normalized Tf-dependent iron uptake and ferritin iron accumulation by transduction of wild type HFE in peripheral blood monocytes from hemochromatosis patients with HFE C282Y mutation [23]. A bone marrow (BM) transplantation study showed the contribution of macrophage HFE expression to iron loading [24]. Thus the dual inductions observed for TfR1 and Hfe in HM from alcohol-fed animals likely synergize to up-regulate iron uptake by these cells.

Reprogramming of iron metabolism for M1 activation

The conclusions from the aforementioned studies demonstrate the importance of upregulated iron uptake and storage as the mechanism of accentuated [LMW-Fe]i signaling for proinflammatory M1 activation of HM via IKK-NF- κ B pathway. This is consistent with the fact that macrophages are the major site of iron metabolism and already known to utilize iron as a vital tool for their host defense mechanisms. Such examples include a bacteriostatic effect on intracellular pathogens by iron deprivation of late endosomes achieved by the transporter Nramp1 unique in macrophages and an anti-microbial action of iron released by macrophages against extracellular microbes [25]. In fact, our results support that these two mechanisms may be coupled to [LMW-Fe]i as [LMW-Fe]i is regulated by Nramp1 and [LMW-Fe]i also results in extracellular iron release (unpublished observation). We would

like to propose that macrophages have evolved to uniquely develop the mechanism by which iron can be utilized as a signaling molecule to support transcriptional regulation of inflammatory and immune-related genes.

II. Loss of Adipogenic Metabolic Reprogramming for Activation of Hepatic Stellate Cells (HSCs)

Activation of HSCs from the cell fate viewpoint

Research in the past three decades disclosed major classes of mediators and signaling pathways for activation of HSCs, the key cellular event in liver fibrogenesis. However, fundamental understanding of HSC activation from the viewpoint of cell fate regulation has been lacking. To this end, we began addressing this question based on the notion that HSCs are of mesodermal origin – which was later confirmed by genetic lineage tracing [26–27]. The mesoderm gives rise to a multi-potent mesenchymal progenitor cells which go through determination and differentiation to osteoblasts, chondrocytes, adipocytes, myocytes, etc. We have proposed 14 years ago that differentiation of HSCs might be similar to that of adipocytes and a series of subsequent studies provided compelling evidence in support of this concept [28–35]. Central to this concept is transcriptional regulation required for adipocyte differentiation including that by PPAR γ , the master regulator of adipogenesis. This adipogenic transcriptional regulation is also required for HSC differentiation. Loss of this regulation as seen due to reduced expression or inhibited activity of PPAR γ , drives loss of a lipogenic phenotype and HSC activation [28–31] and forced expression of PPAR γ in activated HSCs causes their reversal to quiescent and differentiated HSCs [30].

Epigenetic repression of Ppar γ rendered by morphogen re-activation

Loss of PPAR γ expression in anti-adipogenic activation of HSCs was shown to be mediated by the methyl-CpG binding protein MeCP2 which is translationally or post-translationally upregulated to form condensed heterochromatin at the *Ppar γ* locus via recruitment of corepressor HP1 at 5' promoter and H3K27 di- or tri-methylation by the PRC2 methyltransferase EZH2 at 3' exons [36]. Our research also showed that morphogens such as Wnt10b, NECDIN, and DLK1 are induced to activate HSCs in part via MeCP2 enrichment to *Ppar γ* [34–35] and knockdown of these morphogens abrogates these effects and reverses HSC activation. Thus, the morphogens induce lipid metabolic reprogramming and the loss of lipogenic phenotype, leading to HSC activation [37] – see a schematic summary shown in Fig. 2.

Fat paradox of steatohepatitis

This anti-adipogenic regulation underlying HSC activation and liver fibrosis is paradoxical to fat accumulation in hepatocytes in part driven by PPAR γ in steatohepatitis [38–39]. In fatty liver disease, PPAR γ induction promotes fat accumulation in hepatocytes while PPAR γ deficiency in HSCs promotes liver fibrogenesis in the same microenvironment. These cell type-specific paradoxical changes deserve further investigation. To this end, a recent publication on differential regulation of PPAR γ by distinct AP-1 dimers, is worth noting. Here, c-Fos dimerized with JunD, c-Jun, JunB are shown to promote PPAR γ activity for the

genesis of NAFLD while c-Fos-Fra-1/2 dimers antagonized PPAR γ and attenuated NAFLD [40]. Differential cross-coupling regulation of PPAR γ in HSCs may exist. Further how *Ppar γ* is epigenetically regulated in hepatocytes in ASH and NAFLD, deserves to be examined.

Summary

The findings discussed in this review, highlight the importance of iron metabolic reprogramming in M1 HM activation and lipid metabolic reprogramming in myofibroblastic activation of HSCs (Fig. 3). As these two distinct cell fate regulation directly contribute to liver inflammation and fibrosis, the identified metabolic alterations may serve as targets for controlling cell fate and therapeutic interventions of chronic liver disease including ALD.

Acknowledgments

The studies described in this review have been supported by NIAAA grants (P50AA011999, R24AA012885, U01AA018663) and Medical Research Service of Department of Veterans Affairs (VA Merit Review: 1101BX001991 and senior research career scientist award).

References

1. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. *Hepatology*. 2001; 34:101–108. [PubMed: 11431739]
2. Lazaro R, Wu R, Lee S, Zhu NL, Chen CL, French SW, Xu J, Machida K, Tsukamoto H. Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. *Hepatology*. 2014; 61:129–40. [PubMed: 25132354]
3. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. *Semin Liver Dis*. 1996; 16:65–82. [PubMed: 8723325]
4. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. *Gastroenterology*. 1998; 114:311–318. [PubMed: 9453491]
5. Uraz S, Aygun C, Sonsuz A, Ozbay G. Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis. *Dig Dis Sci*. 2005; 50:964–969. [PubMed: 15906776]
6. Valerio LG Jr, Parks T, Petersen DR. Alcohol mediates increases in hepatic and serum nonheme iron stores in a rat model for alcohol-induced liver injury. *Alcohol Clin Exp Res*. 1996; 20:1352–1361. [PubMed: 8947310]
7. Otagawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, Ikeda K, Nakajima Y, Ikura Y, Ueda M, Arakawa T, Hato F, Kawada N. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. *Am J Pathol*. 2007; 170:967–980. [PubMed: 17322381]
8. Yuan XM. Apoptotic macrophage-derived foam cells of human atheromas are rich in iron and ferritin, suggesting iron-catalysed reactions to be involved in apoptosis. *Free Radic Res*. 1999; 30:221–231. [PubMed: 10711792]
9. Kennedy JJ, Chandler DB, Jackson RM, Fulmer JD. Reduction in bleomycin-induced lung hydroxyproline content by an iron chelating agent. *Chest*. 1986; 89:123S–125S. [PubMed: 2419047]
10. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. *Brain*. 2000; 123(Pt 12):2423–2431. [PubMed: 11099445]
11. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. *Ann N Y Acad Sci*. 2004; 1012:179–182. [PubMed: 15105265]

12. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K, Nakashima T, Okanoue T. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. *Hepatol Res.* 2006; 36:315–321. [PubMed: 16971174]
13. Yano M, Hayashi H, Yoshioka K, Kohgo Y, Saito H, Niitsu Y, Kato J, Iino S, Yotsuyanagi H, Kobayashi Y, Kawamura K, Kakumu S, Kaito M, Ikoma J, Wakusawa S, Okanoue T, Sumida Y, Kimura F, Kajiwar E, Sata M, Ogata K. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. *J Gastroenterol.* 2004; 39:570–574. [PubMed: 15235875]
14. Tsukamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S, Brittenham GM. Experimental liver cirrhosis induced by alcohol and iron. *J Clin Invest.* 1995; 96:620–630. [PubMed: 7615836]
15. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. *Gastroenterology.* 2002; 122:281–289. [PubMed: 11832443]
16. Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. *Am J Physiol.* 1997; 272:G1355–G1364. [PubMed: 9227470]
17. Tsukamoto H, Lin M, Ohata M, Giulivi C, French SW, Brittenham G. Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. *Am J Physiol.* 1999; 277:G1240–G1250. [PubMed: 10600822]
18. Xiong S, She H, Takeuchi H, Han B, Engelhardt JF, Barton CH, Zandi E, Giulivi C, Tsukamoto H. Signaling role of intracellular iron in NF-kappaB activation. *J Biol Chem.* 2003; 278:17646–17654. [PubMed: 12637578]
19. Chen L, Xiong S, She H, Lin SW, Wang J, Tsukamoto H. Iron causes interactions of TAK1, p21ras, and phosphatidylinositol 3-kinase in caveolae to activate IkappaB kinase in hepatic macrophages. *J Biol Chem.* 2007; 282:5582–5588. [PubMed: 17172471]
20. Xiong S, She H, Zhang AS, Wang J, Mkrtchyan H, Dynnyk A, Gordeuk VR, French SW, Enns CA, Tsukamoto H. Hepatic macrophage iron aggravates experimental alcoholic steatohepatitis. *Am J Physiol Gastrointest Liver Physiol.* 2008; 295:G512–G521. [PubMed: 18599584]
21. Atkinson PG, Barton CH. High level expression of Nramp1G169 in RAW264. 7 cell transfectants: analysis of intracellular iron transport. *Immunology.* 1999; 96:656–662. [PubMed: 10233755]
22. Knutson MD, Vafa MR, Haile DJ, Wessling-Resnick M. Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. *Blood.* 2003; 102:4191–4197. [PubMed: 12907459]
23. Montosi G, Paglia P, Garuti C, Guzman CA, Bastin JM, Colombo MP, Pietrangelo A. Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. *Blood.* 2000; 96:1125–1129. [PubMed: 10910932]
24. Makui H, Soares RJ, Jiang W, Constante M, Santos MM. Contribution of Hfe expression in macrophages to the regulation of hepatic hepcidin levels and iron loading. *Blood.* 2005; 106:2189–2195. [PubMed: 15914561]
25. Jiang X, Baldwin CL. Iron augments macrophage-mediated killing of *Brucella abortus* alone and in conjunction with interferon-gamma. *Cell Immunol.* 1993; 148:397–407. [PubMed: 8495498]
26. Asahina K, Tsai SY, Li P, Ishii M, Maxson RE Jr, Sucov HM, Tsukamoto H. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. *Hepatology.* 2009; 49:998–1011. [PubMed: 19085956]
27. Asahina K, Zhou B, Pu WT, Tsukamoto H. Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. *Hepatology.* 2011; 53:983–995. [PubMed: 21294146]
28. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. *J Biol Chem.* 2000; 275:35715–35722. [PubMed: 10969082]

29. Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. *J Biol Chem*. 2004; 279:11392–11401. [PubMed: 14702344]
30. She H, Xiong S, Hazra S, Tsukamoto H. Adipogenic transcriptional regulation of hepatic stellate cells. *J Biol Chem*. 2005; 280:4959–4967. [PubMed: 15537655]
31. Yavrom S, Chen L, Xiong S, Wang J, Rippe RA, Tsukamoto H. Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. *J Biol Chem*. 2005; 280:40650–40659. [PubMed: 16216869]
32. Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. *J Gastroenterol Hepatol*. 2006; 21 (Suppl 3):S102–S105. [PubMed: 16958658]
33. Cheng JH, She H, Han YP, Wang J, Xiong S, Asahina K, Tsukamoto H. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. *Am J Physiol Gastrointest Liver Physiol*. 2008; 294:G39–G49. [PubMed: 18006602]
34. Zhu NL, Wang J, Tsukamoto H. The Necdin-Wnt pathway causes epigenetic peroxisome proliferator-activated receptor gamma repression in hepatic stellate cells. *J Biol Chem*. 2010; 285:30463–30471. [PubMed: 20663865]
35. Zhu NL, Asahina K, Wang J, Ueno A, Lazaro R, Miyaoka Y, Miyajima A, Tsukamoto H. Hepatic stellate cell-derived delta-like homolog 1 (DLK1) in liver regeneration. *J Biol Chem*. 2012
36. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. *Gastroenterology*. 2010; 138:705–714. [PubMed: 19843474]
37. Tsukamoto H, Zhu NL, Wang J, Asahina K, Machida K. Morphogens and hepatic stellate cell fate regulation in chronic liver disease. *J Gastroenterol Hepatol*. 2012; 27 (Suppl 2):94–98. [PubMed: 22320925]
38. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, Gonzalez FJ. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. *J Clin Invest*. 2003; 111:737–747. [PubMed: 12618528]
39. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GS, Lopez M, Seppanen-Laakso T, Ashcroft FM, Oresic M, Vidal-Puig A. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. *PLoS Genet*. 2007; 3:e64. [PubMed: 17465682]
40. Hasenfuss SC, Bakiri L, Thomsen MK, Williams EG, Auwerx J, Wagner EF. Regulation of steatohepatitis and PPARgamma signaling by distinct AP-1 dimers. *Cell Metab*. 2014; 19:84–95. [PubMed: 24411941]

Fig. 1.

A schematic diagram depicting how peroxynitrite (ONOO^-) is generated by iNOS and NADPH oxidase to stimulate $[\text{LMW-Fe}]$ response from a chelatable pool of iron for activation of IKK and NF- κ B in LPS or $\text{TNF}\alpha$ -treated macrophages. The inhibitors indicated in red are used to demonstrate the involvement of iNOS, NADPH oxidase, superoxide anion, peroxynitrite, and $[\text{LMW-Fe}]$ in this pathway: L-NIL, L-N6-(1-iminoethyl)lysine; dnRAC1, a dominant negative mutant of Rac1; Cu, Zn-SOD, superoxide dismutase; FeTTPS, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron (III) chloride; L1, 1,2-dimethyl-3-hydroxypyridin-4-one; HBED, N,N'-bis-2-hydroxybenzylethlenediamine-N,N'-diacetic acid. B. A schematic summary of how Fe^{2+} generated by the $[\text{LMW-Fe}]$ response, activates p21Ras and TAK1 in caveolin-1 positive endocytic compartments and their interactive activation of PI3K and downstream kinases for IKK activation. In these pathways, superoxide anion ($\text{O}_2^{\cdot-}$) inhibits protein tyrosine phosphatase (PTP) leading to activation of c-Src (Src) and then p21Ras. At the same time $\text{O}_2^{\cdot-}$ activates TAK1 via K63-linked TRAF6 polyubiquitination (TRAF6-(K63)polyUb) and its association with TAK1 via TAB. Activation of p21Ras and TAK1 results in activation of MEK1 and NIK, respectively, which phosphorylate IKK for activation. P21Ras and TAK1 also contribute to activation of PI3K, further supporting IKK activation.

Fig. 2. Differentiation (quiescence) of HSCs requires transcriptional regulation known to be essential for adipocyte differentiation from preadipocytic fibroblasts including the master adipogenic regulator, PPAR γ . PPAR γ expression is epigenetically repressed by MeCP2 and EZH2 in activation of HSCs, and this mode of repression is under the control of re-activated morphogens such as NECDIN, Wnt10b, DLK1, and SHH.

Fig. 3.

Hepatic macrophages undergo M1 activation to induce liver inflammation while myofibroblastic (MF) cell fate regulation of HSCs drives liver fibrogenesis. For these cell fate regulations, cell-type specific and unique metabolic reprogramming is involved in a manner dependent on morphogens.